Muscle Cell Mediated Therapy for Stress Urinary Incontinence: An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells.
Phase of Trial: Phase II
Latest Information Update: 16 May 2017
At a glance
- Drugs Autologous muscle-derived stem cell therapy Cook MyoSite (Primary)
- Indications Stress incontinence; Urinary incontinence
- Focus Adverse reactions
- Acronyms IND1
- Sponsors Cook MyoSite
- 16 May 2017 Results from NCT00847535, NCT01008943 and NCT01382602 studies, presented at the 112th Annual Meeting of the American Urological Association.
- 30 Jan 2015 New trial record